Arvana (AVNI) Stock Price, News & Analysis

Company Overview

Arvana, Inc. (NASDAQ: AVNI) is a molecular diagnostics company focused on the development and commercialization of rapid, high-sensitivity tests for gastrointestinal diseases and therapeutic drug monitoring. Leveraging a proprietary, label-free biosensor platform, Arvana delivers quantitative assays designed to aid clinicians in the diagnosis and management of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company’s core products aim to improve patient outcomes by providing same-day results for biomarker and therapeutic drug levels, streamlining the treatment decision process for gastroenterologists and laboratory partners.

Since its founding in 2015 as a spin-out from Northwestern University research, Arvana has expanded its operations to include a CLIA-certified laboratory in Frederick, Maryland, and a commercial presence across North America. The company is actively pursuing regulatory approvals and strategic partnerships to introduce its diagnostic assays in Europe and the Asia-Pacific region. In addition to its flagship therapeutic drug monitoring service, Arvana’s pipeline includes next-generation tests for disease activity markers, genetic risk profiling, and microbiome-based analyses, all built on the same versatile sensor technology.

Arvana’s leadership team blends expertise in clinical diagnostics, life sciences, and pharmaceutical commercialization. Under the direction of its executive officers and supported by a board of advisors with backgrounds in gastroenterology and precision medicine, the company has secured key collaborations with leading academic medical centers and specialty laboratories. By integrating advanced analytical techniques with standard clinical workflows, Arvana aims to establish itself as a trusted partner for healthcare providers seeking faster, more actionable data in the management of complex gastrointestinal conditions.

Key Stats

• Today's Range: $0.28 to $0.50
• 50-Day Range: $0.21 to $0.50
• 52-Week Range: $0.11 to $0.66
• Volume: 6,820 shs
• Average Volume: 3,241 shs
• Market Capitalization: N/A
• P/E Ratio: 25.82
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AVNI Stock Analysis - Frequently Asked Questions

How have AVNI shares performed this year?

Arvana's stock was trading at $0.5935 at the beginning of the year. Since then, AVNI shares have decreased by 16.1% and is now trading at $0.4980.

When did Arvana's stock split?

Arvana's stock split on the morning of Thursday, March 30th 2023.The 3-1 split was announced on Thursday, March 30th 2023. The newly issued shares were issued to shareholders after the closing bell on Thursday, March 30th 2023. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

How do I buy shares of Arvana?

Shares of AVNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Financial Services
• Industry: Shell Companies
• Sub-Industry: Trading
• Current Symbol: NASDAQ:AVNI
• CIK: 1113313
• Web: N/A
• Phone: (801) 232-7395
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 25.82
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A